Separate terms with OR to return results that match either term.
 
Clear All

628 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9039 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Jan. 1, 2016 In Use
NA Bosutinib Bosulif 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Bosutinib Bosulif 500 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
C9076 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 July 23, 2021 Sept. 27, 2021 No Longer Used
Q2054 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Sept. 27, 2021 In Use
NA Zanubrutinib Brukinsa 80mg Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2019 In Use
J0594 Busulfan Busulfex 1 mg Chemotherapy Alkylating Agent Alkylsulfonate No 1999 Jan. 1, 2007 In Use
NA Cabozantinib Cabometyx 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use

Found 628 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.